Drugmakers spent $3M in Vermont

20 April 2009

A report issued by the Attorney General for Vermont, USA, William Sorrell (Democrat), has revealed that 78 pharmaceutical firms spent  in excess of $2.9 million in 2008 on marketing to physicians, clinics  and universities in the northeastern state. The Vermont administration  is campaigning to end drugmakers' ability to prevent publication of  the recipients names where a "trade secret" is alleged by the sponsor.

The leading companies involved were USA-based Eli Lilly, Forest  Pharmaceuticals, Merck & Co and Pfizer, as well as Swiss drug major  Novartis, according to the report. Over 80% of recorded marketing  expenditure was categorized as "trade secrets."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight